secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001831283-22-000082
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer opts into LianBio's RSV drug sisunatovir rights in China & Singapore; $20M upfront, up to $135M milestones
--------------------------------------------------------------------------------

- $20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.
- Up to $135M in potential development and commercial milestone payments plus tiered low single-digit percent of net sales.
- Pfizer assumes all development/commercial costs in the region and releases LianBio from its royalty and milestone obligations to ReViral.
- LianBio expects the transaction to extend cash runway through end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/0001831283-22-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/lian-20221216.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer